Maarten Ligtenberg

Maarten Ligtenberg is the Chief Executive Officer at Flindr Therapeutics since March 2020, leading the development of innovative precision oncology medicines through the Immunogram Drug Discovery Engine. Prior to this role, Maarten served as a Postdoctoral Researcher at The Netherlands Cancer Institute from October 2015 to July 2020, and as a PhD Candidate at Karolinska Institutet from September 2010 to September 2015, focusing on passive and active immunity in immunotherapy, particularly through DNA vaccination. Maarten's earlier academic experience includes an MSc internship at Karolinska Institutet and an MSc thesis position at Wageningen University, culminating in degrees from Wageningen University & Research and a Doctor of Philosophy in Tumor Immunology from Karolinska Institutet.